Mononuclear leukocyte ADP-ribosylation as an indicator of immune function in malignant-glioma patients treated with betamethasone for cerebral edema.
Glioma patients receiving corticosteroids (16 mg/day betamethasone) were examined for evidence of immune cell dysfunction by using quantitative estimates of adenosine diphosphate (ADP)-ribosylation in peripheral mononuclear leukocytes as the physiological indicator. The duration of daily treatment with corticosteroids varied from 0 to 35 days at the time of collection of the blood samples. Even after adjustment for covariate factors such as age, sex, smoking habits, alcohol use, antiepileptic medications, and tumor grade, there still remained a highly significant dose-dependent inverse relationship between constitutive and hydrogen peroxide-induced mononuclear leukocyte ADP-ribosylation levels and the duration of corticosteroid treatment (beta coefficients -0.40 and -0.29, respectively; p less than 0.03). No other variable under consideration significantly influenced ADP-ribosylation levels after statistical adjustment. These data support a mutual interdependence of mononuclear leukocyte ADP-ribosylation and corticosteroid-induced immune cell dysfunction in vivo.
Pero
R W
RW
Department of Molecular Ecogenetics, University of Lund, Sweden.
Salford
L G
LG
Strömblad
L G
LG
Andersson
C
C
D001623:Betamethasone / Q000627:therapeutic use*; D001929:Brain Edema / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005910:Glioma / Q000150:complications / Q000201:enzymology / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011065:Poly(ADP-ribose) Polymerases / Q000097:blood / Q000187:drug effects*; D015173:Supratentorial Neoplasms / Q000150:complications / Q000201:enzymology / Q000276:immunology*
D001623:Betamethasone; D011065:Poly(ADP-ribose) Polymerases